IMPACT THERAP-B (07630.HK): EU Approves Senaparib for Ovarian Cancer
NewTimeSpace News: On 17 November 2026, IMPACT Therapeutics, Inc (stock code: 7630) published an announcement under Rule 13.09 of the Listing Rules and the inside information provisions of Part XIVA of the Securities and Futures Ordinance that the European Commission has granted final approval for its self-developed drug senaparib, sold overseas as Sepalna®, for maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer.
The approval follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. Senaparib is described as the first China-origin PARP inhibitor approved by the EU for first-line maintenance treatment across the full population of advanced ovarian cancer, marking a further step for domestic targeted cancer drugs in Europe.
Senaparib is a novel, highly active PARP1/2 inhibitor whose molecular structure provides target selectivity and a wide safety margin. Its capsules were approved by China's National Medical Products Administration in January 2025 for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved a complete or partial response to platinum-based chemotherapy, and were included in the national reimbursement list in December 2025.
The Company is advancing global clinical and regulatory development, lifecycle management and combination studies, and cautioned under Rule 18A.05 that it cannot guarantee eventual marketing of the drug in licensed territories.
- Hong Kong Recently Listed Stocks Daily Report: DKE Rises 22.93% to Lead the Electronic Paper Theme, Pharmaceutical Names Mixed-20261113
- HK Stock Connect Insight | IMPACT THERAP-B (07630.HK) Reports 316.8% H1 Revenue Growth, Down 34.32% Since Stock Connect Inclusion
- IMPACT THERAP-B (07630.HK): Board Approves Up to HK$100m H-Share Buyback
- IMPACT THERAP-B (07630.HK): senaparib FLAMES median PFS hits 38.7 months
- HK Recently Listed Stocks Watch | IMPACT THERAP-B (07630.HK) down 9.59%, 13.93 million cornerstone shares to be unblocked on 13 November, ALLIST's furmonertinib misses Phase III primary endpoint